Tonghua Jinma announced that amviacridine succinate tablets, an innovative chemical class 1 drug independently developed by the company and with completely independent intellectual property rights, were included in the “National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug Catalogue” for the first time. The indication is the treatment of mild and moderate symptoms of Alzheimer's disease. The medical insurance classification number is anticholinesterase drug 401. The agreement is valid from January 1, 2027 to December 31, 2028. The “National Health Insurance Catalogue” will be officially implemented on January 1, 2027.

Zhitongcaijing · 2d ago
Tonghua Jinma announced that amviacridine succinate tablets, an innovative chemical class 1 drug independently developed by the company and with completely independent intellectual property rights, were included in the “National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug Catalogue” for the first time. The indication is the treatment of mild and moderate symptoms of Alzheimer's disease. The medical insurance classification number is anticholinesterase drug 401. The agreement is valid from January 1, 2027 to December 31, 2028. The “National Health Insurance Catalogue” will be officially implemented on January 1, 2027.